

# LISAvienna Highlights

Spring & Summer 2020

**Life Sciences in Vienna:  
A few milestones from the  
last decade**

page 3

**aws BoB - Best of Biotech:  
Celebrating the winners**

page 8

# VIENNA LIFE SCIENCES HUB IN THE HEART OF EUROPE



Dear readers!



At the beginning of a new decade we want to take our time to review the development of Vienna's life sciences community. On the next page, you will find some milestones from the last ten years.

Our unique start-up ecosystem, together with experienced entrepreneur networks and negotiation skills, have yielded spectacular equity investments and licensing deals. These are enabling product candidates to advance toward clinical development stages or to enter markets worldwide. We invite you to read the recent examples included in this folder and to join us at upcoming trade shows and partnering conferences. There will be many opportunities to network with the entrepreneurs who are driving these success stories.

Do you plan to put your own business ideas into practice? LISAvienna is available to discuss your vision. Our technology experts offer free consultations about sponsorship, private financing options, infrastructure in Vienna, development partners, leading customers and internationalization.

We also invite you to explore the Austrian Life Sciences Directory and our online news section to discover more information about the innovative companies available in Vienna. Follow us on LinkedIn or Twitter and sign up for our e-newsletter to stay up to date!

We hope you enjoy reading the spring & summer edition of our Highlights folder. Don't hesitate to reach out to us and our team for further details or to ask about how we and our network partners can support your business.

Peter Halwachs and Johannes Sarx  
LISAvienna Executive Board

## Life Sciences in Vienna at a Glance



## LISAvienna – Connecting Life Sciences

We offer core services at no charge

Joint life science platform for the advancement of life sciences in Vienna



Personalized support for innovative biotech, pharmaceutical and medical device companies

- in Vienna,
- that develop and market
- new products, services and processes

Connecting companies with development partners and key customers.

## Meet us at trade shows & exhibitions

<b>BIO-Europe Spring 2020</b> Paris, March 23-25, 2020	<b>BIO International Convention</b> San Diego, June 8-11, 2020
<b>DMEA 2020</b> Berlin, April 21-23, 2020	<b>AACC 2020</b> Chicago, July 26-30, 2020
<b>dHealth 2020</b> Vienna, May 18-20, 2020	<b>Life Sciences Baltics 2020</b> Vilnius, Sept. 30 – Oct. 1, 2020
<b>MedTech Forum</b> Berlin, May 25-27, 2020	<b>EFIB 2020</b> Frankfurt/Main, October 5-6, 2020
<b>SLAS Europe 2020</b> Vienna, June 2-5, 2020	<b>BIO-Europe 2020</b> Munich, October 26-28, 2020

in cooperation with:



We reserve the right to make changes.



Need a lab for your start-up in Vienna? Please contact the LISAvienna team!



## Boehringer Ingelheim Office Hours in Vienna

In collaboration with LISAvienna, IMP and the Vienna BioCenter, Boehringer Ingelheim invites the biomedical community to join personalized one-on-one consulting sessions in Vienna.

## Stay up to date on the life sciences in Vienna

Follow us on LinkedIn @LISAvienna or Twitter @lifesciencevie and sign up for our e-newsletter

# Life Sciences in Vienna: A few milestones from the last decade

As 2020 marks the start of a new decade, it's a good time to look back on the last ten years and recall some of the highlights LISAvienna had been privileged to witness.

**2018**

**Octapharma** to invest **€142m** in Vienna following the opening of a new R&D facility

**1<sup>st</sup> Boehringer Ingelheim Office Hours** in Vienna

**Shire** celebrates 65<sup>th</sup> anniversary in Austria and becomes part of **Takeda**

**2016**

**MedUni Vienna / AKH: €2.2bn** to be invested until 2030

Founding of **Complexity Science Hub Vienna**

**2014**

Roche to acquire **Dutalys**: upfront cash payment of \$134m and up to \$355m milestone payments

**Vienna Open Lab** doubles capacity

**2012**

Celebrating **10 years of LISAvienna**

**Baxter** invests €100m in Austria

**Savira** signs agreement with Roche worth up to €240m

**2<sup>nd</sup> LISAvienna Medtech Award** at the aws BoB - Best of Biotech business plan competition

**2010**

**1<sup>st</sup> LISAvienna Medtech Award** at the aws BoB - Best of Biotech business plan competition

**MedUni Vienna** opens Anna Spiegel Research Building

**APEIRON** announces licensing deal with GSK worth up to €235m

Founding of the **Vienna BioCenter Core Facilities** with public funding from the federal government and the City of Vienna of up to €52m

Foundation of **EQ-BOKU VIBT GmbH** to boost shared use of advanced scientific equipment and services

## 2019

Vienna Business Agency to establish **Startup Labs** at the Vienna BioCenter

**Ottobock in Austria: 50<sup>th</sup> anniversary**

**Themis Bioscience** €40m Series D funding

**KHAN-I Fund & wings4innovation** launched

Prolongation of funding for the **Austrian Centre of Biotechnology (acib)**

**HOOKIPA** announced **IPO**

**BIO-Europe Spring** in Vienna

**IPO Marinomed** at the Vienna Stock Exchange

**5<sup>th</sup> LISAvienna Medtech Award** at the aws BoB - Best of Biotech business plan competition

## 2017

**Arsanis** (now X4 Pharmaceuticals) **IPO**

**APEIRON Biologics**: EU market approval for immunotherapy of high-risk neuroblastoma

**IMP** opens **new building**

**mySugr** acquired by Roche

**Boehringer Ingelheim** ground breaking ceremony: **€700m** investment

Foundation of the **Vienna Cancer Center**

**4<sup>th</sup> LISAvienna Medtech Award** at the aws BoB - Best of Biotech business plan competition

## 2015

**Nabriva** **IPO**

**BOKU** celebrates **70 years of Food and Biotech Research**

**Pfizer** celebrates 40 years of TBE vaccine production in Austria

**3<sup>rd</sup> LISAvienna Medtech Award** at the aws BoB - Best of Biotech business plan competition

## 2013

**BIO-Europe in Vienna** breaks all previous attendance records

**Valneva** goes public

## 2011

**CeMM**, the Research Center for Molecular Medicine of the Austrian Academy of Sciences: Inauguration of its new building

**New lab space** at the Vienna BioCenter's Marxbbox

**1<sup>st</sup> Vienna Life Science Report** published

*This list is not exhaustive.*

## Virusure

has been acquired by Asahi Kasei Medical. Services and team members will remain unchanged.

[www.virusure.com](http://www.virusure.com)



Vienna's Mayor Michael Ludwig to test Ottobock's Paexo shoulder exoskeleton while paying a visit to the company's facilities in Vienn

**Startup labs.  
Vienna Biocenter.**

*Themis Bioscience*  
raises €40 million in a Series D financing round backed by US/EU consortium to support pivotal study and expand clinical pipeline.  
[www.themisbio.com](http://www.themisbio.com)

**Pfizer** invests €50 million to renew and extend its facilities in Austria and is constructing an international center for quality control.  
[www.pfizer.at](http://www.pfizer.at)

**Marinomed Biotech AG:**  
Detailed clinical data show rapid onset action by Budesolv to alleviate hay fever.  
[www.marinomed.com](http://www.marinomed.com)

## Vienna BioCenter Business News

- **Curetis Group company Ares Genetics and BGI Group** collaborate to offer next-generation sequencing and PCR-based Coronavirus (2019-nCoV) testing in Europe
- **ERS Genomics** and **Aelian Biotechnology** announce CRISPR/Cas9 license agreement enabling Aelian's unique screening platform
- **Eveliqure's** efforts to develop a Shigella-ETEC combination vaccine for travelers and children in resource-poor countries is supported by the Wellcome Trust
- **HOOKIPA Pharma** to announce significant milestones in the development of Cytomegalovirus, HIV and HBV vaccines and an immunotherapeutics product candidate for the treatment of HPV-16-positive cancers
- **Lexogen** to launch several new products to advance transcriptome analyses worldwide
- **Phenaris** launches computational models to predict ligand-transporter interactions
- **SCARLETRED in cooperation with A1:** City of Vienna to fund 5G project focusing on telemedical solutions for wound treatment during home care in Vienna
- **Valneva** announces a new \$85m financing arrangement with the leading US healthcare funds Deerfield and OrbiMed

[www.viennabiocenter.org](http://www.viennabiocenter.org)

## Successful crowdfunding campaigns completed


piurimaging and SzeleSTIM, both from Vienna, raised more than €800,000 from 670 investors. This will speed up the market entry of revolutionizing tomographic ultrasound solutions and a highly innovative medical device for pain treatment.  
[www.piurimaging.com](http://www.piurimaging.com) [www.szelestim.com](http://www.szelestim.com)

**Let's talk business.  
Let's talk Vienna.**

**APEPTICO**  
has signed a Framework Agreement with Haisco Pharmaceutical Group Co., Ltd.  
[www.apeptico.com](http://www.apeptico.com)

**TAmiRNA** to update on osteomiR™:  
Exciting new data on the mechanisms and utility of microRNA bone biomarkers are out now.  
[www.tamirna.com](http://www.tamirna.com)

© BOKU Medienstelle/Christoph Gruber



### BOKU Vienna:

Researchers including Thomas Gaßler and Diethard Mattanovich to succeed in converting a *Pichia pastoris* yeast strain from a heterotroph into an autotroph capable of growth on CO<sub>2</sub>.

## Explore the Austrian life sciences directory!

The database includes profiles from companies and major research and education institutes and covers the following areas:

- Biotechnology
- Digital Health
- Pharmaceuticals
- Medical Devices

[www.lifesciencesdirectory.at](http://www.lifesciencesdirectory.at)



### ACellIT

is a newly founded clinical-stage company focused on developing APN401, a novel siRNA-based Cell Therapy, targeting Cbl-b, a master immune checkpoint. APN401 has already demonstrated safety and disease stabilization in Phase 1a and Phase 1b investigator-initiated studies. The ACellIT team is looking for investors and/or partners to bring this exciting technology forward to the next stage of development.

[www.apeiron-biologics.com/acellit](http://www.apeiron-biologics.com/acellit)

### usePAT GmbH

announces Business Angel Investment and aws Seedfinancing.

[www.usepat.com](http://www.usepat.com)

## ALREADY CERTIFIED?



Apply for the IHE methodology (ISO/TR 28380) for developing interoperability specifications for an existing healthcare environment:  
[academy.technikum-wien.at](http://academy.technikum-wien.at)



Technikum Wien Academy is the only IHE accredited training provider worldwide.

## aws: New program structure

Austria Wirtschaftsservice Gesellschaft mbH (aws) is the promotional bank of the Austrian federal government and is 100% owned by the Republic of Austria. It has significantly simplified and restructured its offerings to make it even easier for companies to find the right funding in the future. The new aws website provides all details in German and English.

[www.aws.at](http://www.aws.at)

## Turn exciting new findings and hypotheses into new drugs!

€60 million are available at the KHAN-I fund for systematic and professional testing and validation to create prototypes of new drugs that indicate an unmet medical need and demonstrate a high potential for further development and commercialization.

Reach out to our experts

- in Austria: [www.w4i.org](http://www.w4i.org)
- in Germany: [www.khanu.de](http://www.khanu.de)

© MedUni Vienna / feelimage



### MedUni Vienna to celebrate the Inventors of the Year 2019:

Congratulations to Petra Heffeter and Walter Berger from the Institute of Cancer Research. Together with scientists from the University of Vienna, they founded the spin-off "**P4 Therapeutics**", which is concentrating on developing new platinum-based anti-cancer drugs.

### ImageBiopsy Lab:

This Vienna-based start-up has become the first Austrian digital health company cleared by the FDA to offer a commercial deep tech algorithm to US radiologists.

[www.imagebiopsylab.com](http://www.imagebiopsylab.com)


More news items available at [www.LISAVienna.at](http://www.LISAVienna.at).

To stay up to date, register for our e-newsletter or follow us on LinkedIn @LISAVienna and Twitter @lifesciencevie !

# Vienna provides 360° support for life sciences start-ups & scale-ups



Starting a biotech or medical device company in Vienna means benefiting from a 360-degree support landscape nurturing a unique life sciences ecosystem. We strongly recommend that you consider Vienna when planning to start up or grow your company at the heart of Europe! Our technology experts are available to provide information about all the support that is available here for developing tomorrow's products, processes and services.



## Vienna:

- Highest quality of life worldwide
- Largest talent pool in the German speaking region
- Outstanding basic and clinical research
- Prime conference destination

## Austria:

- Stable political and economic framework
- 14% research tax credit
- Maximum corporate tax rate: 25%
- Tailor-made funding opportunities

**LISAvienna**  
life science austria  
LISAvienna.at

We accompany you on your way to success.  
Enter the ecosystem now!



NEWS • NEWS • NEWS • NEWS • NEWS • NEWS • NEWS

**Ares Genetics GmbH**, a Curetis Group company, and the Chinese genomics company BGI Group announced that the companies are collaborating to make molecular testing for the new coronavirus 2019-nCoV available in Europe. This will allow public health institutions and hospitals to do their own outbreak monitoring, infection control and epidemiology.

[www.ares-genetics.com](http://www.ares-genetics.com)

**GBA Group Pharma (ABF)** completes its expansion and scale-up project in Vienna, making available increased storage space for IMP and IND products, a GMP warehouse and five packaging suites. This makes the company one of the few in Europe capable of meeting Brexit-related demands from clients doing business in the EU.

[www.abf-pharma.com](http://www.abf-pharma.com)

**Medicus AI**, the Vienna-based health tech company, announces that it has received a Class I Medical Device CE Mark for its mobile application. The CE certification mark is a key milestone because products bearing the CE mark can be freely sold throughout the EU. It also is important for territories ranging from South America to China.

[www.medicus.ai](http://www.medicus.ai)



# Medical Devices and In-vitro Diagnostics LISAVIENNA REGULATORY CONFERENCE

**Vienna's medical device and digital health business sector is growing. This is reflected by the large number of participants at the Regulatory Conference we organized at the end of 2019. Slide decks are available at [www.LISAVienna.at](http://www.LISAVienna.at). If you were unable to make it to the conference, we invite you to rerun the main messages or read through the presentations.**

The new regulations in the EU require certificates for a growing number of healthcare products, raise the standards to be met by existing medical devices and in-vitro diagnostics and create new tasks for hospitals, for example. At the same time, the number of Notified Bodies able to deal with medical devices and in-vitro diagnostics that have been developed and produced for the EU market is dwindling.

Companies, whether large or small, and healthcare organizations are busy preparing for the EU's new Medical Device and In-Vitro Diagnostics Regulations.

Our Regulatory Conference provided ample opportunities to discuss hot topics with outstanding experts.

**We thank our partners and speakers for all their valuable contributions:**

- AIHTA - Austrian Institute for Health Technology Assessment GmbH
- AIT - Austrian Institute of Technology GmbH
- BSI Group Deutschland GmbH
- BASG - Bundesamt für Sicherheit im Gesundheitswesen
- en.co.tec Schmid KG – Consulting & Akademie für Medizinprodukte und IVD
- FH Technikum Wien
- GS1 Austria GmbH
- mdc - medical device certification GmbH
- MedUni Vienna / Vienna General Hospital
- QMD Services GmbH



## LISAVienna Regulatory Conference 2020

Register for our electronic newsletter and the event mailing list to receive an invitation later this year.

# aws BoB - Best of Biotech Celebrating the Winners

On behalf of the Austrian Federal Ministry for Digital and Economic Affairs, aws recently staged an international biotech, medtech and digital health business plan competition. Boehringer Ingelheim, LISAvienna and Roche were supporters of the contest. The LISAvienna Medtech Prizes were awarded to the Cornea Dome Lens Project and AVVie. We congratulate all the winners and look forward to seeing you successfully bring your innovative products to the market!

## Winners in the Early Track

### Biotech/Pharma Category: LightMatters Project

LightMatters' innovative Opto Fluidic Force Induction (OF2i) technology is based on a sophisticated combination of bio photonics and microfluidics. It is the first continuous real-time Process Analytical Tool (PAT) for the documentation of exact design and reproducibility of nano materials and will benefit various industries including pharma and biotech.

<https://biophysik.medunigraz.at/>

### Digital Health Category: PredictingHealth Project

The PredictingHealth project focuses on developing and implementing machine-learning-based, patient-related predictive models for clinical use. Its first product is a tool for predicting the risk of unexpected events for patients in hospitals. This tool will enable clinical staff to adapt monitoring routines for high-risk patients.

### Medtech Category: Cornea Dome Lens Project

The cornea dome lens (CDL) team is developing a camera-based imaging device to create standardized high-resolution photographs of the ocular surface for professional use. The CDL is designed as a stand-alone imaging device and will yield quantitative image data applicable to telemedical use.

[www.occyo.com](http://www.occyo.com)

## Winners in the Start-up Track

### Biotech/Pharma Category: Lithos Crop Protect GmbH

Lithos focuses on responsible plant protection as a valuable and sustainable contribution to securing success in agriculture. CornProtect has been developed to protect corn against the Western Corn Rootworm, which is spreading increasingly throughout Europe. The new non-toxic, biological and highly effective solution is based



on pheromones and works as a target-specific “contraceptive.” This alternative to neonicotinoids reduces root damages below the threshold and therefore avoids yield losses.

[www.lithosprotect.at](http://www.lithosprotect.at)

### Digital Health Category: MyMind GmbH

MyMind's first product is a neurofeedback game called Brain Hero. Using a mobile EEG plus tablet, brain waves are measured, and users receive visual feedback on their concentration and relaxation levels. Regular training sessions of just 15 minutes per day visibly improve brain fitness. Brain Hero will be aimed for children with autism where the company is conducting research. Brain Hero will be also the basis to tackle other neurological issues such as ADHD or Dementia.

[www.brainhero.life](http://www.brainhero.life)

### Medtech Category: AVVie GmbH

Angel Valve Vienna (AVVie), a MedUni Vienna spin-off, is developing “Mitral Butterfly,” an implantable device that uses a minimally invasive procedure to repair leaky mitral valves. The single-step procedure to correct specific heart valve defects using the newly developed device takes less than 12 minutes and eliminates the need for open heart surgery. Consequently, it speeds up the post-operative recovery of patients and shortens the time spent in hospital.

[www.angelvalve.com](http://www.angelvalve.com)



**LISAvienna**  
Life Science Austria Vienna  
Walcherstrasse 11A  
1020 Vienna, Austria

**PHONE** +43 (0) 1 50175 358  
**FAX** +43 (0) 1 50175 900  
**E-MAIL** [office@LISAvienna.at](mailto:office@LISAvienna.at)  
**WEB** [www.LISAvienna.at](http://www.LISAvienna.at)

LISAvienna is a joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.